Compare McKesson Corporation (MCK) vs ArcelorMittal SA (MT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs ArcelorMittal SA — how do they compare? McKesson Corporation trades at $930 (market cap $106.14B), while ArcelorMittal SA trades at $64.02 (market cap $47.06B). The key difference: McKesson Corporation is far larger — about 2.3× ArcelorMittal SA's market cap, and ArcelorMittal SA pays the higher dividend (0.96%). Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and ArcelorMittal SA for 36 Days on average.
| MCK | MT | |
|---|---|---|
Market Cap | $106.14B | $47.06B |
Volume | 794,405 | 1,545,197 |
Sector | Health | Basic Materials |
52-Week High | $995.69 | $78.74 |
52-Week Low | $725.17 | $36.91 |
Typical Hold Time | 74 Days | 36 Days |
Enterprise Value | $112.67B | $56.63B |
Dividend Yield | 0.41% | 0.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $930.25, up 0.93% with strong bullish momentum after recent earnings beats and positive news flow. The stock shows robust technical strength with moving averages signaling bullish alignment and price trading near resistance at $926. Fundamentally, revenue growth accelerated to $359.1 billion in 2025 with consistent profitability, though thin margins remain a characteristic of the distribution business model. Recent catalyst includes the CVS Health partnership extension through 2032, reinforcing long-term revenue visibility.
Outlook remains positive with 81% analyst buy ratings and $956.43 consensus target suggesting 2.8% upside. Key opportunities include oncology/GLP-1 growth drivers and operational efficiency gains, while risks center on drug pricing pressure, policy uncertainty, and competitive threats. The company's improved cash flow generation and debt reduction support financial stability amid sector headwinds.
ArcelorMittal (MT) trades at $62.32, down 4.4% today, with technical indicators signaling bearish momentum. The stock shows mixed fundamentals with revenue declining from $79.8B in 2022 to $61.4B in 2025, though net income improved to $3.2B. Recent news highlights operational disruptions at its Ukrainian plant with a potential $1B impairment charge, while analyst consensus remains positive with a $74.33 price target.
The outlook is cautious due to geopolitical risks and declining revenue trends, but valuation metrics appear reasonable with P/E of 26.2 and P/B of 0.86. Investment opportunity exists if European operations stabilize and growth projects deliver, though investors face headwinds from steel demand volatility and ongoing Ukraine-related impairments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →
